Logo Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults ; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Zilebesiran, Elebsiran, Mivelsiran, ALN-6400, and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
Employees
2,500
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
30
Last Close Price
297.69USD
Average target price
441.31USD
Spread / Average Target
+48.24%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALNY Stock
  4. ETFs Alnylam Pharmaceuticals, Inc.
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!